---
title: treatment of chronic myelogenous leukemia (CML)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> 🌱 來自: [[chronic myelogenous leukemia (CML)]]


# treatment of chronic myelogenous leukemia (CML) 

(Lancet 2015;385:1447; Hematol Oncol Clin North Am2017;31:577)

[[hypomethylating agents|HMA]]: azacitidine or decitabine

## Tyrosine kinase inhibitors (TKI)

> ❌ abl kinase activity.

---

![🔍](https://i.imgur.com/JAWSrLm.png)

---

* 1st gen:
	* [[imatinib]], 1st TKI against [[BCR-ABL1]] (NEJM 2017;376:917)
	* 400mg daily may 800mg

* 2nd gen:
	* [[nilotinib]],  [[dasatinib]],  bosutinib.
	* consider if high [[Sokal score]], ↑ response but ↑ toxicity.
	* No survival difference.

* 3rd gen:
	* [[ponatinib]];
	* a/w ↓ risk of disease progress of treatment of chronic myelogenous leukemia (CML)
	* preferred for int-high risk,
	* but ↑ toxicity

---

* Imatinib, dasatinib, nilotinib, & bosutinib approved for 1st line Rx.
* Nilotinib, dasatinib, bosutinib, ponatinib, & asciminib approved for resistant disease;
* only ponatinib & asciminib effective on T315I mutation (NEJM 2012;367:2075, Blood 2021;138:2031).

---

* STAMP (allosteric inhibitor): asciminib (NEJM 2019;381:2315); after ≥2 prior TKIs

* Resistance: due to ↑ BCR-ABL1 expression, often 2/2 ABL kinase mutation or amplification

* [[Side effects of tyrosine kinase inhibitor]]

* [[TKI discontinuation]]:

* Consider allogeneic HSCT for AP and BP.

* CML in pregnancy: hydroxyurea & all TKIs contraind. If Rx needed, IFN (only option).

* [[Milestones of Therapy of treatment of chronic myelogenous leukemia (CML)]]

